Phospho-PAK4 (S474) Antibody

What is the biological significance of PAK4 phosphorylation at the S474 position?

PAK4 is a serine/threonine protein kinase that plays critical roles in multiple cellular signaling pathways. Phosphorylation at S474 represents an important activation mechanism for PAK4, triggering conformational changes that enable its kinase activity. This phosphorylation event is particularly important because it occurs following activation by various effectors including growth factor receptors or active CDC42 and RAC1, resulting in a conformational change and subsequent autophosphorylation on several serine and/or threonine residues. Once activated, phosphorylated PAK4 regulates cytoskeleton organization, cell migration, growth, proliferation, and cell survival pathways .

How do PAK4, PAK5, and PAK6 phosphorylation events differ in their regulatory functions?

While PAK4, PAK5, and PAK6 share homologous phosphorylation sites (S474, S560, and S602 respectively), their regulatory functions exhibit important differences:

These isoforms phosphorylate overlapping but distinct sets of downstream targets, allowing for tissue-specific and context-dependent signaling pathways. For instance, PAK4 specifically phosphorylates integrin beta5/ITGB5 to regulate cell motility and ARHGEF2 to activate the downstream target RHOA, influencing focal adhesion assembly .

What cellular compartments typically contain phosphorylated PAK4?

Phosphorylated PAK4 exhibits a complex distribution pattern across cellular compartments. According to fractionation studies, substantial amounts of PAK4 are present in whole cell lysates, cytoplasmic fractions, and nuclear fractions. This distribution pattern has been verified through fractionation techniques that enrich for nuclear and cytoplasmic markers . The nuclear localization of phosphorylated PAK4 suggests potential roles in transcriptional regulation or nuclear cytoskeletal organization beyond its better-characterized cytoplasmic functions. This distribution pattern is particularly important when designing experiments to study PAK4 activity in different cellular contexts .

What are the critical considerations when selecting between monoclonal and polyclonal antibodies for phospho-PAK4 detection?

When selecting between monoclonal and polyclonal antibodies for phospho-PAK4 detection, researchers should consider several experimental factors:

For phospho-specific detection, monoclonal antibodies like the rabbit recombinant monoclonal antibodies described in the search results offer superior specificity for the phosphorylated form of PAK4 (S474), PAK5 (S560), and PAK6 (S602) . This specificity is crucial when the research question focuses on activation state rather than total protein levels.

How can researchers validate the specificity of phospho-PAK4 antibodies for experimental applications?

Validating phospho-PAK4 antibody specificity requires a multi-faceted approach:

• Phosphatase Treatment Control: Treat half of your sample with lambda phosphatase to remove phosphorylation and confirm antibody specificity for the phosphorylated form.

• Stimulation-Inhibition Test: Stimulate cells with known PAK4 activators (e.g., growth factors) with and without specific PAK inhibitors to demonstrate signal modulation.

• Knockdown/Knockout Validation: Use siRNA knockdown or CRISPR knockout of PAK4 to confirm signal specificity, as demonstrated in the PAK4 interactome studies where knockdown resulted in decreased F-actin formation .

• Peptide Competition: Pre-incubate the antibody with phosphorylated and non-phosphorylated peptides corresponding to the immunogen to confirm phospho-specificity.

• Cross-reactivity Assessment: Test the antibody against phosphorylated forms of related proteins (PAK5, PAK6) if studying a specific isoform, particularly important since some antibodies detect multiple phosphorylated PAK isoforms .

Successful validation should show signal disappearance under dephosphorylation conditions or in knockout samples, while maintaining signal in phosphorylation-promoting conditions.

When should researchers consider using a pan-phospho-PAK antibody versus isoform-specific antibodies?

The decision between pan-phospho-PAK antibodies (detecting PAK4, PAK5, and PAK6) and isoform-specific antibodies depends on the research question:

Use pan-phospho-PAK antibodies when:

• Studying conserved signaling pathways involving multiple PAK isoforms

• Investigating total PAK activity in systems with redundant PAK functions

• Performing initial screening experiments to identify PAK involvement

• Working with tissues where multiple PAK isoforms are co-expressed

Use isoform-specific antibodies when:

• Investigating isoform-specific functions and targets

• Studying PAK4-specific interactors as identified in the interactome studies

• Analyzing tissues with differential PAK isoform expression

• Validating isoform-specific knockdown or knockout experiments

The MP01723 and similar antibodies that recognize phosphorylated forms of PAK4 (S474), PAK5 (S560), and PAK6 (S602) are suitable for studying conserved PAK functions across isoforms , while isoform-specific antibodies would be necessary for distinguishing unique functions of each PAK protein.

What are the optimal protein extraction and preservation methods for maintaining phospho-PAK4 integrity?

Maintaining phospho-PAK4 integrity during extraction requires careful consideration of phosphatase activity inhibition and protein denaturation:

• Lysis Buffer Composition:

  • Use RIPA or NP-40 based buffers supplemented with phosphatase inhibitors (sodium orthovanadate, sodium fluoride, β-glycerophosphate)

  • Include protease inhibitors to prevent degradation

  • Maintain cold temperature (4°C) throughout extraction

• Sample Processing Protocol:

  • Rapidly harvest cells with direct lysis to minimize dephosphorylation

  • For tissue samples, snap-freeze in liquid nitrogen immediately after collection

  • Perform subcellular fractionation on ice with phosphatase inhibitors present in all buffers, as demonstrated in the PAK4 interactome study

• Storage Considerations:

  • Store lysates at -80°C with minimal freeze-thaw cycles

  • For long-term storage, consider adding glycerol (10%) as a cryoprotectant

  • Aliquot samples to avoid repeated freeze-thaw cycles

These protocols are particularly important when studying phospho-PAK4 since the phosphorylation status can rapidly change due to cellular phosphatase activity.

What optimization strategies improve Western blot detection of phospho-PAK4?

Optimizing Western blot detection of phospho-PAK4 requires attention to several technical factors:

• Transfer Optimization:

  • Use PVDF membranes (0.45 μm) for better protein retention

  • Optimize transfer time and voltage based on protein size (PAK4: ~72 kDa)

  • Consider wet transfer systems for more consistent results with phosphoproteins

• Blocking and Antibody Incubation:

  • Use BSA-based blocking solutions (3-5%) rather than milk (which contains phosphatases)

  • Dilute primary antibodies (like MP01723) at 1:1000 to 1:2000 in BSA-based buffer

  • Include phosphatase inhibitors in antibody dilution buffers

  • Optimize incubation temperature (4°C overnight often yields best results for phospho-epitopes)

• Signal Detection Enhancement:

  • Use enhanced chemiluminescence (ECL) substrates optimized for phosphoprotein detection

  • Consider signal enhancers specific for phosphoprotein detection

  • Implement fluorescent secondary antibodies for multiplex detection and quantification

• Controls:

  • Include positive controls (lysates from cells treated with growth factors)

  • Run phosphatase-treated samples as negative controls

  • Consider loading control optimization (phosphorylation-independent proteins)

These strategies have been validated in research applications using anti-phospho-PAK4 antibodies like those described in the search results .

How can flow cytometry protocols be optimized for intracellular phospho-PAK4 detection?

Optimizing flow cytometry for intracellular phospho-PAK4 detection requires specific protocol adjustments:

• Fixation and Permeabilization:

  • Use paraformaldehyde (2-4%) for fixation to preserve phospho-epitopes

  • Select appropriate permeabilization reagents (methanol for phospho-epitopes often yields superior results)

  • Optimize fixation time (10-20 minutes) to balance epitope preservation and antibody accessibility

• Staining Protocol:

  • Block with 5% BSA in PBS to reduce non-specific binding

  • Dilute anti-phospho-PAK4 antibodies (like MP01723) at 1:100 to 1:200 in BSA-based buffer

  • Include phosphatase inhibitors in all buffers

  • Extend incubation times (45-60 minutes) for optimal antibody penetration

• Controls and Validation:

  • Use isotype controls matched to the host species and antibody class

  • Include biological controls (stimulated vs. unstimulated cells)

  • Validate with phosphatase treatment to confirm specificity for phosphorylated epitope

• Instrument Settings:

  • Optimize voltage settings for detection channel

  • Implement compensation when using multiple fluorophores

  • Consider using branched DNA amplification for low abundance targets

These optimizations are particularly important since flow cytometry applications for phospho-PAK4 detection are specifically mentioned in the antibody specifications .

How does PAK4 phosphorylation influence its interactions with the cytoskeletal regulatory machinery?

PAK4 phosphorylation plays a critical role in cytoskeletal regulation through several mechanistic pathways:

• Regulation of Cofilin Activity: Phosphorylated PAK4 targets and inactivates the protein phosphatase SSH1, leading to increased inhibitory phosphorylation of cofilin. This decreased cofilin activity promotes stabilization of actin filaments, directly impacting cytoskeletal dynamics .

• LIMK1 Phosphorylation: Active phospho-PAK4 phosphorylates LIMK1, which in turn also inhibits cofilin activity, creating a dual regulatory mechanism for actin filament stabilization .

• N-WASP VCA Domain Phosphorylation: Research has demonstrated that PAK4 directly phosphorylates the VCA domain of N-WASP, specifically at Serines 484 and 485. This phosphorylation event influences N-WASP-mediated actin polymerization .

• F-actin/G-actin Equilibrium Regulation: PAK4 knockdown experiments have shown that PAK4 significantly affects the balance between filamentous (F) and globular (G) actin. When PAK4 is depleted, the equilibrium shifts toward G-actin with markedly less F-actin detected, suggesting PAK4's important role in promoting actin polymerization and filament stability .

• Arp2/3 Complex Interaction: PAK4 interactome studies have identified novel interactions between PAK4 and the Arp2/3 complex subunit ARPC2, suggesting a role in regulating actin nucleation and branching .

These findings demonstrate the multifaceted role of phosphorylated PAK4 in cytoskeletal regulation, where it acts as a central node connecting multiple regulatory pathways affecting actin dynamics.

What methodological approaches can differentiate between PAK4, PAK5, and PAK6 specific signaling in experimental systems?

Differentiating between PAK4, PAK5, and PAK6 specific signaling requires sophisticated experimental approaches:

• Isoform-Specific Knockdown/Knockout Strategies:

  • Design isoform-specific siRNAs targeting non-conserved regions

  • Create isoform-specific CRISPR/Cas9 knockout cell lines

  • Use inducible knockdown systems to control the timing of isoform depletion

• Phosphorylation Site-Specific Antibodies:

  • Use antibodies that distinguish between the different phosphorylation sites (S474 for PAK4, S560 for PAK5, S602 for PAK6)

  • Validate specificity through peptide competition assays with isoform-specific phosphopeptides

• Expression System Approaches:

  • Express phospho-mimetic mutants (S→D) or phospho-deficient mutants (S→A) of specific PAK isoforms

  • Create chimeric proteins to identify isoform-specific functional domains

  • Use rescue experiments with wild-type or mutant PAK isoforms in knockout backgrounds

• Interactome Analysis:

  • Implement isoform-specific immunoprecipitation followed by mass spectrometry

  • Compare interactomes between PAK isoforms to identify unique binding partners

  • Use proximity labeling techniques (BioID, APEX) to identify isoform-specific signaling complexes

• Tissue-Specific Analysis:

  • Leverage the differential expression patterns of PAK isoforms (PAK5 predominantly in brain, PAK6 in prostate and testis)

  • Use tissue-specific knockout models to isolate isoform-specific functions

These approaches can build upon the PAK4 interactome studies described in the search results, which identified 313 PAK4 interactors with 30 overlapping with the PAK1 interactome .

How can researchers investigate the temporal dynamics of PAK4 phosphorylation during cell signaling events?

Investigating temporal dynamics of PAK4 phosphorylation requires techniques capable of resolving signaling events with high temporal resolution:

• Time-Course Stimulation Studies:

  • Stimulate cells with growth factors or activators for varying time periods

  • Collect samples at multiple time points (e.g., 0, 5, 15, 30, 60 minutes)

  • Analyze phospho-PAK4 levels by Western blotting with phospho-specific antibodies

  • Quantify band intensities and normalize to total PAK4 or loading controls

• Live-Cell Imaging Approaches:

  • Generate cells expressing FRET-based PAK4 phosphorylation biosensors

  • Implement phosphorylation-sensitive fluorescent probes

  • Perform time-lapse microscopy during stimulation

  • Quantify signal changes in real-time at subcellular resolution

• Phosphoproteomics Time-Course Analysis:

  • Perform phosphoproteome enrichment at multiple time points

  • Use stable isotope labeling (SILAC, TMT, iTRAQ) for quantitative comparison

  • Analyze phosphorylation dynamics of PAK4 and its substrates simultaneously

  • Build kinetic models of PAK4 signaling networks

• Single-Cell Analysis:

  • Implement flow cytometry with phospho-specific antibodies at multiple time points

  • Analyze population heterogeneity in phospho-PAK4 response

  • Correlate with cell cycle phase or other parameters

  • Use mass cytometry (CyTOF) for multiplexed phosphorylation analysis

• Pharmacological Manipulation:

  • Use kinase inhibitors with varying pretreatment times

  • Apply phosphatase inhibitors to trap phosphorylated states

  • Implement washout experiments to study dephosphorylation kinetics

These approaches build upon the methodologies used in the PAK4 interactome studies, which employed fractionation and immunoprecipitation techniques to study PAK4 signaling complexes .

What are the common technical challenges in phospho-PAK4 antibody applications and their solutions?

Researchers frequently encounter several technical challenges when working with phospho-PAK4 antibodies:

Additionally, phospho-specific antibodies may show variations in sensitivity depending on the surrounding amino acid sequence context. Researchers should validate antibodies in their specific experimental system and consider using multiple antibodies targeting different epitopes when possible .

How can researchers accurately interpret changes in phospho-PAK4 signal in complex biological contexts?

Accurate interpretation of phospho-PAK4 signals requires consideration of multiple factors:

• Normalization Strategies:

  • Always normalize phospho-PAK4 signal to total PAK4 protein levels

  • Implement housekeeping protein controls appropriate for the experimental condition

  • Consider using loading controls specific to the subcellular fraction being analyzed

• Multiple Detection Methods:

  • Validate key findings with at least two independent methods (e.g., Western blot and immunofluorescence)

  • Correlate phospho-PAK4 levels with downstream substrate phosphorylation (e.g., LIMK1)

  • Implement functional assays to confirm the biological significance of observed changes

• Context Considerations:

  • Account for cell cycle phase, as PAK4 plays a role in cell-cycle progression

  • Consider cell density effects on cytoskeletal organization and PAK4 activity

  • Evaluate the influence of cell type-specific PAK isoform expression patterns

• Quantitative Analysis:

  • Use digital image analysis for objective quantification

  • Implement statistical analysis appropriate for the experimental design

  • Consider nonlinear relationships between phosphorylation and downstream effects

• Integrative Analysis:

  • Correlate phospho-PAK4 changes with alterations in the actin cytoskeleton

  • Examine relationships between PAK4 phosphorylation and its interactome components

  • Connect observed changes to functional outcomes like cell migration or proliferation

These interpretation frameworks are particularly important given PAK4's diverse roles in cytoskeletal regulation, cell migration, growth, proliferation, and cell survival pathways .

What controls are essential for validating phospho-PAK4 antibody specificity in diverse experimental systems?

Essential controls for validating phospho-PAK4 antibody specificity include:

• Genetic Controls:

  • PAK4 knockdown/knockout: Signal should be significantly reduced or eliminated

  • PAK4 overexpression: Should increase signal proportionally

  • Phospho-site mutants: S474A mutant should show no reactivity with phospho-specific antibodies

• Phosphorylation State Controls:

  • Phosphatase treatment: Lambda phosphatase treatment should eliminate signal

  • Kinase activators: Treatment with growth factors or active CDC42/RAC1 should increase signal

  • Kinase inhibitors: PAK inhibitors should reduce phospho-signal while maintaining total PAK4 levels

• Antibody Validation Controls:

  • Peptide competition: Pre-incubation with phospho-peptide should block signal

  • Multiple antibodies: Use antibodies from different sources targeting the same phospho-site

  • Host species controls: Include isotype controls matched to the antibody host species

• Cross-Reactivity Assessment:

  • Test in systems with known expression profiles of PAK4, PAK5, and PAK6

  • Validate in tissues with differential PAK isoform expression

  • For pan-PAK antibodies (detecting PAK4, PAK5, and PAK6), confirm reactivity with each isoform individually

• Application-Specific Controls:

  • For Western blotting: Include molecular weight markers to confirm band size

  • For immunofluorescence: Include secondary-only controls to assess background

  • For flow cytometry: Use isotype controls and fluorescence-minus-one (FMO) controls

These controls are critical for ensuring the reliability of results obtained with phospho-PAK4 antibodies in research applications .

How might single-cell analysis techniques advance our understanding of PAK4 phosphorylation heterogeneity in complex tissues?

Single-cell analysis techniques offer unprecedented opportunities to understand PAK4 phosphorylation heterogeneity:

• Single-Cell Phosphoproteomics:

  • Mass spectrometry-based approaches for quantifying phosphorylation at the single-cell level

  • Correlation of PAK4 phosphorylation with other signaling nodes

  • Identification of cell subpopulations with distinct PAK4 activity profiles

• Spatial Transcriptomics Integration:

  • Combining single-cell PAK4 activity measurements with spatial information

  • Mapping PAK4 phosphorylation patterns in relation to tissue architecture

  • Correlating with localized expression of PAK4 regulators and effectors

• Live-Cell Single-Molecule Imaging:

  • Tracking individual PAK4 molecules and their phosphorylation state

  • Measuring kinetics of phosphorylation/dephosphorylation at the single-molecule level

  • Visualizing PAK4 interactions with the cytoskeleton in real-time

• Multi-Parameter Cytometry:

  • Simultaneous measurement of multiple phosphorylation sites on PAK4 and its substrates

  • Correlation with cell cycle status, differentiation markers, and metabolic state

  • Building comprehensive signaling profiles at single-cell resolution

These approaches would extend the interactome studies described in the search results to the single-cell level, providing insights into how PAK4 signaling heterogeneity contributes to tissue function and disease processes.

What novel therapeutic strategies might emerge from better understanding PAK4 phosphorylation networks?

Enhanced understanding of PAK4 phosphorylation networks could lead to several therapeutic innovations:

• Targeted Inhibition Strategies:

  • Development of phosphorylation site-specific inhibitors rather than ATP-competitive inhibitors

  • Design of protein-protein interaction disruptors targeting PAK4's interaction with specific effectors

  • Creation of degraders (PROTACs) specifically targeting phosphorylated PAK4

• Pathway-Selective Modulation:

  • Targeting specific downstream effects of PAK4 (e.g., cytoskeletal regulation vs. survival signaling)

  • Developing context-specific inhibitors that function only in certain cellular compartments

  • Creating combination therapies targeting PAK4 along with synergistic pathways

• Biomarker Development:

  • Using phospho-PAK4 status as a predictive biomarker for therapeutic response

  • Developing diagnostic tools to measure PAK4 activity in patient samples

  • Creating companion diagnostics for PAK4-targeted therapies

• Tissue Engineering Applications:

  • Manipulating PAK4 phosphorylation to control cell migration in engineered tissues

  • Modulating cytoskeletal dynamics through PAK4 for improved tissue architecture

  • Enhancing cellular survival in transplanted tissues through PAK4 signaling modulation

These therapeutic directions would build upon the fundamental understanding of PAK4's role in cytoskeletal regulation, cell migration, and survival signaling described in the search results .

How might the PAK4 interactome vary between normal and disease states, and what methodological approaches could reveal these differences?

Investigating PAK4 interactome differences between normal and disease states requires sophisticated comparative approaches:

• Quantitative Interactomics:

  • Apply SILAC, TMT, or iTRAQ labeling to compare PAK4 interactomes between normal and diseased cells

  • Implement BioID or APEX proximity labeling with quantitative readouts

  • Use crosslinking mass spectrometry to capture transient interactions that may be altered in disease

• Disease-Specific Tissue Analysis:

  • Perform PAK4 immunoprecipitation from patient-derived tissues

  • Compare interactomes across disease progression stages

  • Correlate interactome changes with clinical outcomes

• Phosphorylation-Dependent Interactome Analysis:

  • Compare interactomes of wild-type PAK4 versus phospho-mimetic or phospho-deficient mutants

  • Analyze how disease-associated mutations affect PAK4 phosphorylation and subsequent interactions

  • Identify phosphorylation-dependent interaction partners using phospho-specific protein arrays

• Spatiotemporal Mapping:

  • Implement live-cell imaging of PAK4 interactions in normal versus disease models

  • Analyze subcellular compartment-specific interactions as described in the PAK4 interactome study

  • Track dynamic changes in the PAK4 interactome during disease progression

• Network Analysis Approaches:

  • Apply computational methods to identify altered interaction motifs in disease

  • Implement machine learning to predict functional consequences of interactome changes

  • Develop network models incorporating PAK4 phosphorylation status and interactome dynamics